中医药调控PPARγ防治骨质疏松症的研究进展  

Research progress of prevention and treatment of osteoporosis by traditional Chinese medicine based on PPARγ

作　　者：吴雪[1] 张惜燕 胡勇 WU Xue;ZHANG Xiyan;HU Yong(Shaanxi University of Chinese Medicine,Xianyang 712046,China)

机构地区：[1]陕西中医药大学,陕西咸阳712046

出　　处：《中国骨质疏松杂志》2024年第3期405-412,共8页Chinese Journal of Osteoporosis

基　　金：陕西省教育厅重点科研计划项目(23JS006,20JS029);陕西中医药大学中医经典理论研究创新团队资助项目(2019⁃YL01)。

摘　　要：骨质疏松症是一种由于骨形成与骨吸收偶联失衡所引起的退行性疾病。过氧化物酶体增殖物激活受体γ(peroxisome proliferation⁃activated receptorsγ,PPARγ)通过调控Wnt/β⁃catenin、CEBPα、OPG/RANKL/RANK信号通路加快骨质疏松症的发生与发展。研究发现,中药可靶向PPARγ调控这些信号通路,促进成骨细胞形成,抑制破骨细胞的吸收作用,从而发挥抗骨质疏松症的作用。本文通过检索PubMed、中国知网、万方、维普等数据库,将近十年收录有关中药通过抑制PPARγ防治骨质疏松症的研究文献进行概括与总结,以期为中药治疗骨质疏松症的深入研究提供参考依据。Osteoporosis is a degenerative disease caused by imbalance between bone absorption and bone formation.Peroxisome proliferation⁃activated receptorsγ(PPARγ)can drive the occurrence and development of OP via Wnt/β⁃catenin,CEBPαand OPG/RANKL/RANK signal pathways.Research has found that traditional Chinese medicine can target PPARγRegulating these signaling pathways,promoting the formation of osteoblasts,inhibiting the absorption of osteoclasts,and thus exerting anti osteoporosis effects.This article indexed databases such as PubMed,CNKI,Wanfang,and VIP,which have included information on how traditional Chinese medicine inhibits PPARγover the past decade.Summarize and conclude the research literature on the prevention and treatment of osteoporosis,in order to provide reference for in⁃depth research on traditional Chinese medicine treatment of osteoporosis.

关 键 词：骨质疏松症 中药 PPARΓ 成骨细胞 破骨细胞 

分 类 号：R274.9[医药卫生—中西医结合]